Avalyn Raises $175 Million In Oversubscribed Series C Financing To Advance Inhaled Pulmonary Fibrosis Programs Into Later Stage Clinical Studies
Avalyn Raises $175 Million In Oversubscribed Series C Financing To Advance Inhaled Pulmonary Fibrosis Programs Into Later Stage Clinical Studies
09/27/23, 10:34 AM
Location
seattleMoney raised
$175 million
Industry
health care
biotechnology
Round Type
series c
Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, announced the closing of an oversubscribed $175 million Series C financing. Avalyn plans to use the funds to continue development of its portfolio of inhalation therapies for interstitial lung disease that improve upon currently approved medications, and advance lead clinical assets, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), into mid-stage clinical trials.